Who Are Weight Loss Medications Not a Good Fit For?
Clear, ethical guidance on when GLP-1 medications like Ozempic, Wegovy, or Zepbound may not be the right choice.
Weight loss medications are one tool among many, and for some people, they introduce more risk than benefit.
If you have ever been told “you can just try it and see,” you are right to pause. That approach ignores medical history, mental health, reproductive goals, and the very real fact that these medications affect appetite, digestion, and nutrition status.
This post walks through situations where GLP-1 medications may not be a good fit, or where careful medical and nutrition oversight is essential.
“Powerful tools require careful use, not casual experimentation.”
Our Approach to Weight Loss Medications
At Whole Lifecycle Nutrition, we take a non-restrictive, physiology-first approach to health. We do not view weight loss medications as a default solution or a substitute for nutrition, movement, or care. These medications may be appropriate in specific medical contexts, but they also carry real risks and tradeoffs.
Our goal in this series is not to persuade anyone to use medication, but to help readers understand when they may help, when they may harm, and when they are simply not the right tool.
Medical Contraindications
There are situations where GLP-1 medications should not be used.
Absolute contraindications include:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN2)
- Known hypersensitivity to the medication or its components
These are based on boxed warnings and prescribing information and should be treated as non-negotiable.
Additional screening and caution considerations
Other medical situations that require careful evaluation include:
- History of pancreatitis
GLP-1 receptor agonists are generally used with caution in people with a history of treated pancreatitis. If pancreatitis is suspected, the medication should be stopped and evaluated. - Severe kidney disease or dehydration risk
GI side effects can lead to dehydration and, in vulnerable patients, acute kidney injury. This is one reason proactive hydration and symptom management are not optional. - Advanced gastroparesis
These medications delay gastric emptying and may worsen symptoms in people with significant motility disorders. - Diabetic retinopathy in people with diabetes
In semaglutide studies in diabetes, early worsening of diabetic retinopathy complications was observed, likely related to rapid glucose improvement rather than a direct drug effect. Current standards recommend assessing retinopathy status when glucose-lowering therapy is intensified and ensuring an eye exam within the last 12 months for many patients with diabetes. - History of suicidal behavior or active ideation
Some product labeling includes warnings related to suicidal behavior and ideation. This does not mean the medication causes psychiatric harm in most people. It does mean screening and monitoring are appropriate when risk is present.
“Screening is not gatekeeping. It is safety.”
A History of Eating Disorders
This section deserves nuance, not a blanket statement.
GLP-1 medications change appetite, hunger cues, and interest in food. For some people, that is helpful. For others, especially those with certain eating disorders, it can be destabilizing.
Restrictive eating disorders
A joint advisory from obesity and nutrition societies notes that restrictive eating disorders are a general contraindication to GLP-1 use. Appetite suppression can reinforce restriction, meal avoidance, and disconnection from internal cues.
This includes:
- Anorexia nervosa, past or present
- Restrictive eating patterns with medical instability or significant fear of eating
- Active severe restriction, even if it does not carry a formal diagnosis
Binge eating disorder
For binge eating disorder, the evidence is more nuanced. Early studies and reviews suggest GLP-1 medications may reduce binge episodes in some individuals by reducing cravings and reward-driven eating. That said, this is not a do-it-yourself situation.
If binge eating is present, best practice is specialist evaluation. Many guidelines recommend referral to both an obesity medicine specialist and an eating disorders specialist when there is a history of eating disorder and GLP-1 therapy is being considered.
Overall psychiatric safety
Large analyses have not shown an overall increase in psychiatric adverse events with GLP-1 receptor agonists and some data suggest improvements in emotional eating and restrained eating behaviors. Individual responses still vary, and people with eating disorder history deserve closer monitoring, not assumptions.
“When restriction has already been part of the story, adding a medication that suppresses appetite is not a neutral intervention.”
Gastrointestinal Conditions That Require Caution
Because GLP-1 medications slow gastric emptying and affect gut motility, certain GI conditions need special caution.
Extra caution is warranted for people with:
- Gastroparesis or delayed gastric emptying
GLP-1 medications significantly delay gastric emptying and are generally not recommended in severe gastroparesis. - Severe GERD or reflux
Delayed emptying can worsen reflux symptoms. Some people need careful meal timing, smaller portions, and avoiding lying down after meals for longer. - Inflammatory bowel disease during active flares
GI side effects can be hard to distinguish from disease activity, and tolerability can be lower during flares. - Chronic constipation not responsive to treatment
Constipation can persist for weeks during dose escalation. If constipation is already severe, GLP-1 therapy can worsen quality of life and risk complications. - History of bowel obstruction or ileus
Slowed motility may increase risk in susceptible individuals.
Procedures requiring anesthesia
Because these medications delay gastric emptying, some anesthesia and procedural guidelines recommend holding GLP-1 medications before procedures to reduce aspiration risk. Protocols vary by institution, so patients should follow their surgical or anesthesia team’s instructions.
“If your gut already struggles, adding another brake may not be helpful.”
Pregnancy, Fertility, and Postpartum Considerations
GLP-1 medications are not used during pregnancy and are generally stopped before conception.
Preconception washout periods
Washout guidance differs by medication:
- Semaglutide (Ozempic, Wegovy): discontinue at least 2 months before a planned pregnancy due to its long half-life.
- Tirzepatide (Zepbound, Mounjaro): discontinue at least 1 month before pregnancy per Canadian labeling. US labeling advises discontinuation when pregnancy is recognized but does not specify a preconception timeframe.
- In practice, guidelines note that several months may be needed for medication elimination and for stabilizing health markers with alternative therapy.
Contraception note for tirzepatide
Tirzepatide delays gastric emptying and may reduce the effectiveness of oral hormonal contraceptives. People using oral contraception should either:
- Switch to a non-oral method, or
- Use a barrier method for 4 weeks after initiation and 4 weeks after each dose escalation
Given the titration schedule, that can mean several months of backup contraception.
Postpartum and breastfeeding
Data are limited. Appetite suppression during postpartum can interfere with recovery, nutrition status, and milk supply in some individuals. Decisions here should be individualized and involve the prescribing clinician.
“Reproductive goals change the risk-benefit equation entirely.”
When Weight Loss Is Not the Right Primary Goal
Not everyone who wants a GLP-1 medication benefits from weight loss as the first intervention.
Caution is warranted when:
- Weight is stable but distress is high
- Fatigue, hormonal symptoms, or GI issues are the main concern
- Under-eating or nutrient deficiency is already present
- Muscle and bone mass are low, or frailty risk is high
- There is sarcopenia risk, especially in older adults
- BMI is in the “normal” range and use would be off-label without a clear medical rationale
In these cases, building nutrition adequacy and strength first may improve symptoms and long-term health more than appetite suppression.
“Weight loss is not always the most helpful starting point.”
Why “Just Try It” Is Not Informed Care
GLP-1 medications are sometimes framed as low-risk experiments. That framing is misleading.
These medications can:
- Change appetite signaling and food intake patterns
- Affect hydration and micronutrient intake
- Worsen certain GI conditions
- Influence muscle and bone mass during weight loss
- Interact with other medications and health conditions
Informed care means:
- Screening for contraindications and risks
- Considering mental health and eating disorder history
- Discussing reproductive goals and contraception
- Planning nutrition and strength support from the start
- Reassessing regularly, not set-and-forget prescribing
“Trying something powerful without a plan is not neutral.”
The Bottom Line
GLP-1 medications can be a great fit for some people and a poor fit for others. That is not failure. That is ethical care.
If you are unsure whether a medication like Ozempic, Wegovy, or Zepbound is appropriate for you, the most important step is not starting quickly. It is screening thoughtfully, clarifying your risks, and building a support plan that protects your health.
“Good care starts with discernment, not urgency.”
Considering Ozempic, Wegovy, Zepbound, or another GLP-1 medication? Our role is not to decide whether medication is right for you, but to support nutrition, muscle preservation, digestion, and long-term health during use or discontinuation.
Work with our team. If you are using or stopping a GLP-1 medication, nutrition and lifestyle support matter. We provide non-restrictive, physiology-based care focused on protecting health during appetite changes, weight shifts, and transitions off medication.
References
- American Diabetes Association Professional Practice Committee. Retinopathy, neuropathy, and foot care: Standards of Care in Diabetes 2026. Diabetes Care. 2026.
- Das SR, Everett BM, Birtcher KK, et al. 2020 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in type 2 diabetes. Journal of the American College of Cardiology. 2020.
- Coppenrath V, Mazyck B. Tirzepatide (Zepbound) for the treatment of obesity. American Family Physician. 2024.
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory. American Journal of Clinical Nutrition. 2025.
- Bartel S, McElroy SL, Levangie D, Keshen A. GLP-1 receptor agonist use in eating disorder populations. International Journal of Eating Disorders. 2024.
- Jebeile H, Danielsen YS, Sumithran P, et al. GLP-1 receptor agonists and changes in eating behaviors and eating disorder risk: a rapid review. Obesity Reviews. 2025.
- Pierret ACS, Mizuno Y, Saunders P, et al. GLP-1 receptor agonists and mental health. JAMA Psychiatry. 2025.
- Tongta S, Sungkaworn T, Pathomthongtaweechai N. GLP-1 receptor agonists in binge eating disorder: a narrative review. International Journal of Molecular Sciences. 2025.
- American Diabetes Association Professional Practice Committee. Management of diabetes in pregnancy: Standards of Care in Diabetes 2026. Diabetes Care. 2026.
- U.S. Food and Drug Administration. Tirzepatide (Zepbound) prescribing information. 2026.
- Kunutsor SK, Seidu S. Safety and tolerability of GLP-1 receptor agonists: a narrative review. Drugs. 2025.
